Just like redox disruptors, a surprising number of “targeted” drugs in advanced stages of clinical testing, including proteasome, MAPK, and mTOR inhibitors, target molecules that are essential to the survival of normal cells and thus not per se cancer cell selective. The gene discussed is MTOR; the disease is cancer.